Delivery Order SPE2DB22D2211-SPE2DB25FSCJX
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,241.46 to AmerisourceBergen Drug Corp for Vyvanse 40 mg capsules (100-count) on July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed-price contract represents a competitively awarded, non-set-aside delivery order for pharmaceutical supply to support federal medical procurement needs. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Vyvanse 60 mg capsules (100-count units) with a contract ceiling value of $1,378.96. This is a firm fixed-price delivery order with an ultimate completion date of August 6, 2025, and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The award was competitively procured with no set-aside designation....
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp, the prime contractor, on August 7, 2025, for the supply of Vyvanse 40 mg capsules (100 count). This competitively awarded, non-set-aside contract carries a ceiling value of $1,161.44 with firm fixed pricing and a completion date of August 8, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a routine pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Vyvanse 40 mg capsules (quantity: 100s) with a contract value of $3,121.30 and an ultimate completion date of July 22, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 40 mg capsules in quantities of 100 units with a ceiling value of $1,337.70. This competitively awarded, non-set-aside contract was executed on August 5, 2025, with an ultimate completion date of August 6, 2025. The delivery order employs firm fixed pricing and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) at a ceiling value of $5,051.16. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is set for ultimate completion by August 6, 2025, and will be fulfilled from the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a ceiling value of $2,917.37 and a completion date of August 11, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and will be performed at the contractor's Conshohocken, Pennsylvania location. The award is executed as a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,238.84 to AmerisourceBergen Drug Corp for the supply of Vyvanse 40 mg capsules (100-count units) on July 24, 2025, with completion scheduled for July 25, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and is being performed at the contractor's Conshohocken, Pennsylvania location. The contract falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 60 mg capsules (100 count) on July 23, 2025, with a ceiling value of $1,456.54 and an ultimate completion date of July 24, 2025. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Vyvanse 50 mg capsules (100-count units) with a contract value of $1,552.17. This competitively awarded, non-set-aside delivery order is structured as a firm fixed price contract with an ultimate completion date of July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under...
- SPE2DB22D2211Indefinite Delivery Contract
- SPE2DB22D2211-SPE2DB25FSCJXDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Vyvanse 40 mg capsules (100 count) with a ceiling value of $4,639.68. This is a firm fixed-price delivery order with no set-aside designation, utilizing competitive procurement procedures. The contract is expected to be completed by August 8, 2025, with performance taking place at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999,999,999.00 pharmaceutical prime vendor agreement running through December 2026. The parent IDC serves as the primary vehicle for supplying a broad range of pharmaceuticals and medical supplies to support military healthcare programs globally, including the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. Vyvanse (lisdexamfetamine) is a controlled substance used for treating attention deficit hyperactivity disorder, representing one of many specialty medications within AmerisourceBergen's extensive federal medical supply portfolio.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.6k | 8/7/25 |